Browse the evidence

Specific fatty acid esters of hydroxy fatty acids (FAHFAs), particularly 5-PAHSA and 9-PAHSA, improve insulin sensitivity and glucose-stimulated insulin secretion.

Research shows that specific fatty acid derivatives called FAHFAs (like 5-PAHSA) can improve how your body handles insulin and glucose. However, this is currently based on animal studies and human observational data, not proven clinical treatments. Do not self-prescribe specific isomers until more clinical trials are available.

Duodenal Mucosal Resurfacing (DMR) significantly improves glycaemic control in Type 2 Diabetes patients by enhancing insulin sensitivity.

Duodenal Mucosal Resurfacing (DMR) is a new, minimally invasive procedure that can help lower blood sugar in Type 2 Diabetes. It works by treating the duodenum to improve insulin sensitivity. Clinical trials show it reduces HbA1c levels, and the more duodenum treated, the better the result. It is a safe option for those who may not respond well to standard treatments.

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.

Off-label use of GLP-1 receptor agonists (specifically semaglutide) for weight loss can precipitate euglycemic starvation ketoacidosis in non-diabetic individuals, primarily through gastrointestinal side effects causing reduced oral intake and starvation.

If you are using GLP-1 medications like semaglutide for weight loss, do not source them from unregulated online pharmacies. The risk of receiving counterfeit or improperly dosed products is real and can lead to severe metabolic issues. If you experience persistent nausea, vomiting, or inability to eat, seek medical attention immediately, as this can lead to euglycemic ketoacidosis—a dangerous condition where your blood becomes acidic despite normal blood sugar levels. Never ignore severe gastrointestinal side effects.

The mitochondrial uncoupler SHO1122147, administered at 200 mg/kg/day, significantly reduces body weight and liver triglycerides in a mouse model of MASH without causing hyperthermia or altering food intake.

This research identifies a specific compound (SHO1122147) that acts as a mitochondrial uncoupler to burn energy directly, leading to significant fat loss and improved liver health in a mouse model of fatty liver disease. Crucially, it achieved this without causing dangerous overheating or reducing the amount of food eaten. While not yet available for humans, it represents a potential future therapeutic class that targets energy expenditure rather than appetite, potentially avoiding the muscle loss and gastrointestinal side effects seen in current popular weight loss drugs.

Post-market surveillance is investigating potential links between GLP-1 receptor agonists and suicidal ideation, as well as an increased risk of thyroid cancer of all histologic subtypes.

Stay informed about post-market surveillance findings. The FDA has issued warnings regarding suicidal behavior, and studies suggest a higher risk of thyroid cancer. Discuss these risks with your healthcare provider and follow current evidence-based counseling.

Dietary supplementation with Docosahexaenoic acid (DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing Betacellulin (BTC) expression, thereby inhibiting the BTC-EGFR-ERBB pathway, reducing hepatic stellate cell proliferation, and lowering TGFβ-2-mediated collagen production.

If you are managing NASH or liver health, the specific type of Omega-3 matters. Research indicates DHA is more effective than EPA at suppressing key liver damage pathways (like Betacellulin and TGFβ-2). While this study is in mice, it suggests prioritizing DHA-rich sources or supplements over generic Omega-3 blends for liver-specific benefits.

GLP-1 receptor agonists (GLP1RAs) do not increase the risk of adverse events compared to other anti-obesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight regain, current data indicates they are not more dangerous than other standard weight loss drugs. The risk of serious complications is low and similar to other options. However, starting these medications more than 12 months after surgery appears to have a lower risk of adverse events than starting them earlier.

Systemic administration of the GIP receptor agonist DA-GIP suppresses inflammation-induced conditioned taste avoidance (CTA) and reduces parabrachial CGRP neuron activation, acting via distinct neural circuits than its anorectic effects.

For individuals experiencing severe nausea or food aversion due to inflammation (e.g., chronic autoimmune conditions or post-infection), standard anti-nausea medications (like ondansetron) or anti-inflammatories (NSAIDs) may not fully resolve the aversion. Emerging GIP-based therapies show promise in specifically targeting the neural circuits responsible for this aversion without necessarily worsening appetite suppression, potentially improving quality of life during inflammatory episodes.

GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.

Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.

Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.

This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.

In 60–65-year-old women, higher intake of long-chain polyunsaturated fatty acids (PUFA) is negatively correlated with skeletal muscle mass, contrary to some previous literature suggesting protective effects.

For women aged 60-65, do not assume that high PUFA intake guarantees muscle preservation. This study found a negative correlation, possibly because those with lower muscle mass increase PUFA intake to compensate. Focus on protein intake and moderate activity as primary drivers.

The Australian Recommended Food Score (ARFS), a measure of overall dietary quality, is not associated with any sarcopenia components (muscle strength, lean mass, or physical performance) in older adults.

Don't just focus on 'eating healthy' in a general sense. This study suggests that general diet quality scores don't predict muscle mass. Instead, focus on ensuring you are getting enough protein and total energy, especially if you are exercising.

Acute ingestion of 2.5g betaine prior to resistance exercise does not improve muscular endurance or total training volume in trained men.

Taking 2.5g of betaine one hour before your workout will not increase the number of reps you can perform or the total weight you lift in that session. If you want to try betaine, you likely need to take it daily for at least 10 days to allow muscle tissue saturation, rather than relying on a single pre-workout dose.

Mild mitochondrial uncoupling promotes true ectopic lipid disposal by dissipating substrate energy as heat, thereby reducing lipid burden in non-adipose tissues without causing compensatory redistribution (the 'ballooning effect').

Current research suggests that 'mild' mitochondrial uncoupling is a promising therapeutic avenue for treating metabolic diseases like fatty liver and diabetes by burning off excess fat as heat. However, these are experimental pharmaceutical interventions (e.g., CRMP, BAM15) not yet available for general use. Natural methods like exercise and cold exposure also induce mild uncoupling and are the current safe way to leverage this mechanism.

Pharmacological weight loss drugs (except specific diabetes drugs like empagliflozin and semaglutide) have not demonstrated improved cardiovascular outcomes or efficacy in reducing visceral/ectopic fat.

Traditional weight loss medications do not protect your heart or reduce dangerous belly fat. If you take them, do not assume your heart risk is gone. Continue lifestyle interventions.

Tirzepatide demonstrates greater clinical potency than semaglutide, potentially due to glucose-dependent insulinotropic polypeptide (GIP) receptor activation increasing energy expenditure.

If you are struggling with weight loss on a GLP-1 drug like semaglutide, ask your doctor about tirzepatide. It targets two hormones (GIP and GLP-1) instead of just one, which may lead to greater weight loss for some people by increasing how much energy you burn.

Time-restricted eating (TRE) with a duration of less than 8 hours per day is associated with an increased risk of cardiovascular mortality.

Be cautious with extreme time-restricted eating. While moderate fasting windows (12-16 hours) may improve insulin sensitivity, restricting your eating to less than 8 hours a day has been linked to higher cardiovascular mortality in large population studies. Stick to moderate approaches.

In patients with Type 2 Diabetes and Heart Failure with reduced ejection fraction (HFrEF), treatment with GLP-1 receptor agonists significantly reduces all-cause mortality and major cardiovascular events compared to DPP-4 inhibitors.

If you have Type 2 Diabetes and reduced heart function (HFrEF), GLP-1 medications (like semaglutide or dulaglutide) are associated with a significantly lower risk of death and heart-related hospitalizations compared to DPP-4 inhibitors. This benefit appears early and persists over 5 years, regardless of age or sex. Discuss these options with your cardiologist, as they may offer cardiovascular protection beyond blood sugar control.

Precision nutrition and individualized interventions may not be sufficient to address obesity at a population level without addressing broader social, economic, and environmental determinants.

When seeking to improve health, look beyond individual diet plans. Advocate for and support policies that make healthy food affordable and accessible, and address social determinants like income and housing, as these are critical for long-term success.

A single meal containing 72g of digestible carbohydrates inhibits ketosis (lipolysis) for several days, with recovery time dependent on baseline fasting insulin levels.

If you are relying on ketosis for fat loss, avoid high-carb meals entirely. A single meal with ~72g of carbs (e.g., bread and jam) can stop fat burning for 2 to 5 days, or indefinitely if your fasting insulin is high. Recovery time depends on your metabolic health; those with higher insulin levels may never recover ketosis within a standard 2-week window.